Pure Global

PICAROS - Acalabrutinib RWE on 1L CLL in Spain - Trial NCT05999877

Access comprehensive clinical trial information for NCT05999877 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Chronic Lymphocytic Leukemia. Target enrollment is 315 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05999877
Recruiting
Trial Details
ClinicalTrials.gov • NCT05999877
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
Non-interventional Cohort Study of Patients Previously Untreated or First-generation BTKi Intolerant With Chronic Lymphocytic Leukemia Describing the First-line Use of Acalabrutinib and Its Real-world Outcomes in Spain: the PICAROS Study

Study Focus

Observational

Sponsor & Location

AstraZeneca

Almeria,Cordoba,Granada,Jaen,Malaga,Sevilla,Zaragoza,Oviedo,Santander,Guadalajara,Toledo,Salamanca,Segovia,Valladolid,Valladolid,Barcelona,Barcelona,Barcelona,Barcelona,Granollers,Hospitalet de Llobre, Spain

Timeline & Enrollment

N/A

Jul 11, 2023

Dec 31, 2026

315 participants

Primary Outcome

Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation.

Summary

This is a multicenter non-interventional study (NIS) on patients with CLL who have been
 treated with acalabrutinib for the first time within the year before the first site
 initiation visit in Spain.

ICD-10 Classifications

Chronic lymphocytic leukaemia of B-cell type
Chronic myelomonocytic leukaemia
Acute myelomonocytic leukaemia
Lymphoid leukaemia
Chronic leukaemia of unspecified cell type

Data Source

ClinicalTrials.gov

NCT05999877

Non-Device Trial